Vito Lepore
Overview
Explore the profile of Vito Lepore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andreano A, Lepore V, Magnoni P, Milanese A, Fanizza C, Testa D, et al.
Syst Rev
. 2024 Dec;
13(1):313.
PMID: 39716260
Background: Heart failure (HF), affecting 1-4% of adults in industrialized countries, is a major public health priority. Several algorithms based on administrative health data (HAD) have been developed to detect...
2.
Ponzio M, Battaglia M, Trojano M, Salivetto M, DEttorre A, Corrado D, et al.
Epidemiol Prev
. 2024 Sep;
48(4-5):361-374.
PMID: 39329242
Registers collecting data from clinical practice (real world data) have gained increasing interest in recent years in the scientific, administrative, and regulatory fields. The value of longitudinal data collection in...
3.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 Sep;
271(10):7066-7068.
PMID: 39231861
No abstract available.
4.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 May;
271(8):5074-5082.
PMID: 38805052
Objectives: We investigated the occurrence and relative contribution of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) to confirmed disability accrual (CDA) and transition to secondary progression (SP)...
5.
Chisari C, Aguglia U, Amato M, Bergamaschi R, Bertolotto A, Bonavita S, et al.
Neurotherapeutics
. 2024 May;
21(4):e00363.
PMID: 38714462
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression...
6.
Lepore V, Paletta P, Bosetti C, Santucci C, Ponzio M, Pupillo E, et al.
Mult Scler Relat Disord
. 2024 May;
87:105638.
PMID: 38713966
Background: The therapeutic scenario in multiple sclerosis (MS) has evolved over recent years with the progressive introduction of new drugs focused to better balance efficacy, safety and management requirements. The...
7.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, et al.
JAMA Neurol
. 2023 Nov;
81(1):50-58.
PMID: 38010712
Importance: Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) are protected...
8.
Mosconi P, Guerra T, Paletta P, DEttorre A, Ponzio M, Battaglia M, et al.
Neurol Sci
. 2023 Jun;
44(11):4001-4011.
PMID: 37311951
Introduction: Over the years, disease registers have been increasingly considered a source of reliable and valuable population studies. However, the validity and reliability of data from registers may be limited...
9.
Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Aguglia U, et al.
Neurol Sci
. 2022 Jun;
43(9):5459-5469.
PMID: 35672479
Background: Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a...
10.
Bertero E, Robusto F, Rulli E, DEttorre A, Bisceglia L, Staszewsky L, et al.
JACC CardioOncol
. 2022 May;
4(1):98-109.
PMID: 35492831
Background: Studies assessing whether heart failure (HF) is associated with cancer and cancer-related mortality have yielded conflicting results. Objectives: This study assessed cancer incidence and mortality according to pre-existing HF...